According to a new research report “Beta-Secretase (BACE) Inhibitors Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” published by P&S Intelligence, BACE inhibitors currently exhibit a pipeline with estimated 15 drug candidates.
Browse the Report Summary at: https://www.psmarketresearch.com/market-analysis/beta-secretase-inhibitors-pipeline-analysis
BACE Inhibitors Exhibit an Emerging Pipeline with 10+ Drug Candidates
The study analysed that the Beta Secretase inhibitors pipeline comprised 15 drug candidates, in different stages of development.
Insights on pipeline segments
As per the findings of the research, most of the pipeline drug candidates of BACE inhibitors are being developed to be administered by oral route.
Alzheimer’s disease drug development receives Fast Track designation
Among BACE inhibitors, AZD3293, a drug candidate of AstraZeneca plc and Eli Lilly and Company, received Fast Track designation by the U.S. Food and Drug Administration (FDA) in August 2016. The FDA’s Fast Track program was designed to expedite the development and review new therapies to treat serious conditions and tackle unmet medical needs.
Major companies collaborate for the development of BACE inhibitors
The research finds that different companies collaborated for the development of BACE inhibitors. Novartis entered in a global collaboration with Amgen to commercialize and develop BACE inhibitor program in September 2015 for Alzheimer's disease.
Some of the key players developing BACE inhibitors are AstraZeneca plc, Eli Lilly & Company, Johnson & Johnson, and others.
BACE Inhibitors Pipeline Analysis